Choline-magnesium trisalicylate modulates acute myelogenous leukemia gene expression during induction chemotherapy

Leuk Lymphoma. 2017 May;58(5):1227-1230. doi: 10.1080/10428194.2016.1225206. Epub 2016 Sep 23.

Authors

Affiliations

¹ a Division of Medical Oncology , Rutgers Cancer Institute of New Jersey, Rutgers the State University of New Jersey , NJ , USA.
² b Department of Biostatistics , Rutgers Biomedical and Health Sciences , Piscataway , NJ , USA.
³ c Child Health Institute , Robert Wood Johnson Medical School, Rutgers the State University of New Jersey , NJ , USA.

PMID: 27659510
DOI: 10.1080/10428194.2016.1225206

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Choline / analogs & derivatives*
Choline / pharmacology
Choline / therapeutic use
Gene Expression Profiling
Gene Expression Regulation, Leukemic / drug effects*
Humans
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / drug therapy
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / metabolism
NF-kappa B / metabolism
Salicylates / pharmacology*
Salicylates / therapeutic use
Signal Transduction
Treatment Outcome

Substances

Antineoplastic Agents
NF-kappa B
Salicylates
choline magnesium trisalicylate
Choline